Literature DB >> 1698781

Binding of human syndecan to extracellular matrix proteins.

K Elenius1, M Salmivirta, P Inki, M Mali, M Jalkanen.   

Abstract

We have isolated a cell surface proteoglycan from a human mammary cell line (HBL-100). This proteoglycan was found to be a human equivalent to mouse syndecan, because (i) it has identical biochemical properties with murine syndecan, including size, charge, buoyant density, and glycosaminoglycan composition, (ii) its core protein has identical size with murine syndecan as studied by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and (iii) the core protein is detected with anti-peptide antibody for the cytoplasmic domain of syndecan. HBL-100 cells also showed high expression of syndecan mRNAs, when probed with mouse syndecan cDNA. The ectodomain of the human syndecan revealed binding to type I collagen fibrils and fibronectin but not to laminin, duplicating the binding properties of murine syndecan. Very interestingly, syndecan did not bind to vitronectin, which is known to contain a heparin binding domain and is one of the major adhesive factors of serum for cultured cells. Syndecans are known to change their glycosaminoglycan composition yielding tissue-type specific polymorphic forms of syndecan (Sanderson, R., and Bernfield, M. (1988) Proc. Natl. Acad. Sci. U. S.A. 85, 9562-9566). The members of this family may thus represent a collection of structurally related matrix receptors that could differ in their interactions due to variation of the ectodomain glycosylation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698781

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Schwann cell type V collagen inhibits axonal outgrowth and promotes Schwann cell migration via distinct adhesive activities of the collagen and noncollagen domains.

Authors:  M A Chernousov; R C Stahl; D J Carey
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

2.  Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells.

Authors:  G David; B van der Schueren; P Marynen; J J Cassiman; H van den Berghe
Journal:  J Cell Biol       Date:  1992-08       Impact factor: 10.539

3.  Isolation and functional analysis of syndecans.

Authors:  Pyong Woo Park
Journal:  Methods Cell Biol       Date:  2017-10-06       Impact factor: 1.441

4.  Proteoglycan synthesis in haematopoietic cells: isolation and characterization of heparan sulphate proteoglycans expressed by the bone-marrow stromal cell line MS-5.

Authors:  Z Drzeniek; B Siebertz; G Stöcker; U Just; W Ostertag; H Greiling; H D Haubeck
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

5.  Type IX collagen interacts with fibronectin providing an important molecular bridge in articular cartilage.

Authors:  Philippa Parsons; Sophie J Gilbert; Anne Vaughan-Thomas; David A Sorrell; Rebecca Notman; Mark Bishop; Anthony J Hayes; Deborah J Mason; Victor C Duance
Journal:  J Biol Chem       Date:  2011-07-15       Impact factor: 5.157

6.  Expression of a Xenopus counterpart of mammalian syndecan 2 during embryogenesis.

Authors:  N D Rosenblum; B B Botelho; M Bernfield
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

Review 7.  Cytokines and proteoglycans.

Authors:  J J Nietfeld
Journal:  Experientia       Date:  1993-05-15

Review 8.  Syndecan family of cell surface proteoglycans: developmentally regulated receptors for extracellular effector molecules.

Authors:  M Salmivirta; M Jalkanen
Journal:  Experientia       Date:  1995-09-29

9.  Analysis of transport and targeting of syndecan-1: effect of cytoplasmic tail deletions.

Authors:  H M Miettinen; S N Edwards; M Jalkanen
Journal:  Mol Biol Cell       Date:  1994-12       Impact factor: 4.138

10.  Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation.

Authors:  P Inki; F Stenbäck; L Talve; M Jalkanen
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.